Hong Kong-traded mainland pharmaceutical companies are positioned to achieve annual profitability driven by accelerating drug revenues and high-value licensing agreements with international partners. The turnaround follows extensive R&D investments as companies capitalize on innovation despite domestic pricing headwinds.

Source: South China Morning Post   Read Full Story